Get the Stockscreener App
8.31
2.25%
-0.12
Lipocine Inc stock is traded at $8.31, with a volume of 54,895.
It is down -2.25% in the last 24 hours and up +6.74% over the past month.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
See More
Previous Close:
$8.43
Open:
$8.29
24h Volume:
54,895
Relative Volume:
0.41
Market Cap:
$45.75M
Revenue:
-
Net Income/Loss:
$-16.35M
P/E Ratio:
-2.7246
EPS:
-3.05
Net Cash Flow:
$-11.88M
1W Performance:
-17.60%
1M Performance:
+6.74%
6M Performance:
+185.12%
1Y Performance:
+143.79%
1-Day Range:
$8.04
$8.60
1-Week Range:
$8.04
$10.46
52-Week Range:
$2.52
$12.37
Lipocine Inc Stock (LPCN) Company Profile
Name
Lipocine Inc
Sector
Industry
Phone
801 994 7383
Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
8.24 | 46.80M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.70 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.45 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
721.77 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.03 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.37 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-12-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-11-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| Dec-08-17 | Resumed | H.C. Wainwright | Buy |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
| Jun-23-15 | Initiated | Canaccord Genuity | Buy |
View All
Lipocine Inc Stock (LPCN) Latest News
Lipocine (LPCN) Expected to Announce Earnings on Thursday - Defense World
Lipocine Files Prospectus to Enable $50M Stock Offering - TipRanks
Lipocine (LPCN) establishes $50M at-the-market common stock sales plan - Stock Titan
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) - Nasdaq
Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock? - Yahoo Finance
LPCN Technical Analysis & Stock Price Forecast - Intellectia AI
Lipocine Files For Common Stock Offering Of Up To $50 MillionSEC Filing - TradingView
LivePerson (NASDAQ: LPCN) increases ATM sales capacity to $50M - Stock Titan
Lipocine (LPCN) Jumps 5.5%: Does the Stock Have More Room to Grow? - Bitget
ETF Watch: Is Lipocine Inc a turnaround storyTreasury Yields & Daily Momentum Trading Reports - baoquankhu1.vn
Can Lipocine Inc. stock beat market expectations this quarterTreasury Yields & Short-Term High Return Ideas - mfd.ru
Lipocine completes patient visits in phase 3 trial for PPD treatment By Investing.com - Investing.com South Africa
Lipocine completes patient visits in phase 3 trial for PPD treatment - Investing.com Nigeria
Lipocine Completes Phase 3 Trial for Postpartum Depression - TipRanks
Lipocine (NASDAQ: LPCN) files updated corporate investor presentation - Stock Titan
Is Lipocine Inc. stock a buy on dips2025 Key Lessons & Proven Capital Preservation Tips - mfd.ru
Is Lipocine Inc. a potential multi baggerMarket Volume Summary & Low Drawdown Momentum Ideas - mfd.ru
Lipocine Announces Late Breaking Oral Presentation of Data from - GuruFocus
Buy Rating Maintained on Lipocine Inc. (LPCN) as Target Climbs to $15 - Finviz
Does Lipocine Inc. stock have upside surprise potential2025 Stock Rankings & Long Hold Capital Preservation Tips - mfd.ru
Why Lipocine Inc. stock is favored by top institutionsJuly 2025 WrapUp & Smart Allocation Stock Reports - mfd.ru
S P Trends: Does Lipocine Inc offer margin of safetyMarket Activity Summary & Short-Term High Return Ideas - baoquankhu1.vn
Lipocine Announces Positive Interim Results for PPD Trial - MSN
Lipocine (LPCN) Price Target Increased by 58.18% to 11.09 - Nasdaq
Market Moves: Can Lipocine Inc ride the EV waveJuly 2025 News Drivers & Precise Swing Trade Alerts - baoquankhu1.vn
EV Market: Is Lipocine Inc a cyclical or defensive stockPortfolio Value Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress By Investing.com - Investing.com South Africa
H.C. Wainwright raises Lipocine stock price target to $15 on PPD trial progress - Investing.com India
Lipocine completes enrollment in phase 3 trial for PPD treatment By Investing.com - Investing.com South Africa
Lipocine Completes Phase 3 Enrollment for Postpartum Depression Drug - TipRanks
Lipocine Inc Completes Enrollment in Phase 3 Trial for PPD Treatment - TradingView
Lipocine completes enrollment in phase 3 trial for PPD treatment - Investing.com
At-home postpartum depression drug from Lipocine tested in 90 women - Stock Titan
CEO Moves: Can Lipocine Inc ride the EV waveJuly 2025 Sector Moves & Fast Gaining Stock Reports - baoquankhu1.vn
Performance Recap: What is TREEs TAM Total Addressable MarketWeekly Market Outlook & Weekly High Return Opportunities - baoquankhu1.vn
LPCN 1154 for postpartum depression continues clinical process after safety review - Contemporary OB/GYN
Liver Cirrhosis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Pfizer, GlaxoSmithKline, Bausch Health, Bristol-Myers Squibb, Mallinckrodt, Cumberland - The Globe and Mail
Lipocine’s PPD drug trial continues after positive safety review By Investing.com - Investing.com India
Lipocine’s PPD drug trial continues after positive safety review - Investing.com
Lipocine Advances Phase 3 Postpartum Depression Drug Trial - TipRanks
Lipocine Inc Reports Progress in Phase 3 Trial for PPD - TradingView — Track All Markets
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PR Newswire
How Lipocine Inc. stock reacts to global recession fearsMarket Activity Report & High Accuracy Investment Entry Signals - ulpravda.ru
How Lipocine Inc. stock performs in stagflationTrade Risk Assessment & AI Forecasted Stock Moves - ulpravda.ru
How Lipocine Inc. stock benefits from strong dollarJuly 2025 Big Picture & Weekly Consistent Profit Watchlists - ulpravda.ru
Why Lipocine Inc. stock is considered a top pickJuly 2025 Big Picture & Fast Gain Stock Tips - Улправда
Why Lipocine Inc. stock could benefit from AI revolutionTrade Performance Summary & Free Fast Gain Swing Trade Alerts - Улправда
What is the fair value of Lipocine Inc. stock nowBear Alert & Reliable Entry Point Trade Alerts - ulpravda.ru
Lipocine Inc Stock (LPCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):